RESUMO
We measured circulating endothelial precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) using four-color multiparametric flow cytometry in the peripheral blood of 84 chronic myeloid leukemia (CML) patients and 65 healthy controls; and vascular endothelial growth factor (VEGF) by quantitative real-time PCR in 50 CML patients and 32 healthy controls. Because of an increase in mCECs, the median percentage of CECs in CML blast crisis (0.0146%) was significantly higher than in healthy subjects (0.0059%, P<0.01) and in the accelerated phase (0.0059%, P=0.01). There were no significant differences in the percentages of CECs in chronic- or active-phase patients and healthy subjects (P>0.05). In addition, VEGF gene expression was significantly higher in all phases of CML: 0.245 in blast crisis, 0.320 in the active phase, and 0.330 in chronic phase patients than it was in healthy subjects (0.145). In conclusion, CML in blast crisis had increased levels of CECs and VEGF gene expression, which may serve as markers of disease progression and may become targets for the management of CML.
Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Crise Blástica/patologia , Células Endoteliais/patologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Células Neoplásicas Circulantes/patologia , Fator A de Crescimento do Endotélio Vascular/genética , Biomarcadores Tumorais/análise , Crise Blástica/sangue , Crise Blástica/genética , Estudos de Casos e Controles , Contagem de Células , Citometria de Fluxo/métodos , Expressão Gênica/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Neovascularização Patológica/patologia , Reação em Cadeia da Polimerase em Tempo Real , Valores de Referência , Estatísticas não Paramétricas , Fator A de Crescimento do Endotélio Vascular/análiseRESUMO
In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles. The remaining patients received high-dose cytarabine (≥1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles). The actual dose received during the entire consolidation period in these patients was calculated, allowing us to divide these patients into 2 additional groups. Group 2 (n=27) received an intermediate-high-dose (<27 g/m2), and group 3 (n=35) received a very-high-dose (≥27 g/m2). Among the 311 patients receiving curative treatment, the 5-year survival rate was 20.2% (63 patients). The cytarabine consolidation dose was an independent determinant of survival in multivariate analysis; age, karyotype, induction protocol, French-American-British classification, and de novo leukemia were not. Comparisons showed that the risk of death was higher in the intermediate-high-dose group 2 (hazard ratio [HR]=4.51; 95% confidence interval [CI]: 1.81-11.21) and the low-dose group 1 (HR=4.43; 95% CI: 1.97-9.96) than in the very-high-dose group 3, with no significant difference between those two groups. Our findings indicated that very-high-dose cytarabine during consolidation in adults with non-promyelocytic AML may improve survival.
Assuntos
Criança , Feminino , Humanos , Masculino , Transtorno do Deficit de Atenção com Hiperatividade/reabilitação , Terapia Cognitivo-Comportamental/métodos , Função Executiva/fisiologia , Inibição Psicológica , Assistência Ambulatorial , Transtorno do Deficit de Atenção com Hiperatividade/psicologia , Transtornos do Comportamento Infantil/psicologia , Memória de Curto Prazo/fisiologia , Metilfenidato/uso terapêutico , Projetos Piloto , Jogos e Brinquedos , Pais/psicologia , Reforço Psicológico , Resultado do Tratamento , Listas de Espera , Conduta ExpectanteRESUMO
The ABO blood group is the most important blood group system in transfusion medicine and organ transplantation. To date, more than 160 ABO alleles have been identified by molecular investigation. Almost all ABO genotyping studies have been performed in blood donors and families and for investigation of ABO subgroups detected serologically. The aim of the present study was to perform ABO genotyping in patients with leukemia. Blood samples were collected from 108 Brazilian patients with chronic myeloid leukemia (N = 69), chronic lymphoid leukemia (N = 13), acute myeloid leukemia (N = 15), and acute lymphoid leukemia (N = 11). ABO genotyping was carried out using allele specific primer polymerase chain reaction followed by DNA sequencing. ABO*O01 was the most common allele found, followed by ABO*O22 and by ABO*A103. We identified 22 new ABO* variants in the coding region of the ABO gene in 25 individuals with leukemia (23.2%). The majority of ABO variants was detected in O alleles (15/60.0%). In 5 of 51 samples typed as blood group O (9.8%), we found non-deletional ABO*O alleles. Elucidation of the diversity of this gene in leukemia and in other diseases is important for the determination of the effect of changes in an amino acid residue on the specificity and activity of ABO glycosyltransferases and their function. In conclusion, this is the first report of a large number of patients with leukemia genotyped for ABO. The findings of this study indicate that there is a high level of recombinant activity in the ABO gene in leukemia patients, revealing new ABO variants.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Alelos , Variação Genética , Leucemia/sangue , Sistema ABO de Grupos Sanguíneos/genética , DNA , Análise Mutacional de DNA , Genótipo , Leucemia/classificação , Reação em Cadeia da Polimerase , Polimorfismo Genético , Sistema ABO de Grupos Sanguíneos/classificaçãoRESUMO
Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18 percent) of them were classified as low risk, 40 (36 percent) as intermediate risk, 33 (29.7 percent) as high intermediate risk, and 18 (16.3 percent) as high risk. Over a five-year period, OS and DFS rates were 71 and 59 percent, respectively, for all patients. For the same time period, OS and DFS rates were 72.8 and 61.3 percent, respectively, for 77 patients treated with CHOP chemotherapy and 71.3 and 60 percent for patients treated with the ProMACE-CytaBOM protocol. There was no significant difference in OS or DFS between the two groups. Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy. Three received allogenic and 8 autologous bone marrow transplantation. For the latter, CR was 62.5 percent and mean OS was 41.1 months. The clinical behavior, CR, DFS, and OS of the present patients were similar to those reported in the literature. We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity.
Assuntos
Humanos , Masculino , Feminino , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica , Linfoma Difuso de Grandes Células B , Intervalo Livre de Doença , Estadiamento de Neoplasias , Indução de Remissão , Análise de Sobrevida , Resultado do TratamentoRESUMO
Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7 percent of blast cells and 20.2 percent of normal bone marrow cells (P<0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to neoplastic cells and protecting normal tissues
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Antibióticos Antineoplásicos , Daunorrubicina , Leucemia Mieloide Aguda , Lipoproteínas LDL , Células-Tronco Neoplásicas , Células da Medula Óssea , Morte Celular , Ésteres do Colesterol , Células K562 , Leucemia Mieloide Aguda , Fosfolipídeos , Receptores de LDL , Reação em Cadeia da Polimerase Via Transcriptase Reversa , RNA MensageiroRESUMO
Objetivo. Comparar o consumo de hemocomponentes entre recém-nascidos (RN) de termo (RNT) e pré-termo (RNPT) e correlacionar esse consumo ao tipo de tratamento dispensado à sua patologia: clínico ou cirúrgico; acidentes hemorrágicos e sobrevida. Casuística e Metodologia. 48 Rns classificados em dois grupos: 26 RNT e 22 RNPT receberam 251 unidades de hemocomponentes: 177 unidades de concentrado de hemácias (CH), 36 de concentrado de plaquetas (CP), 30 de plasma fresco congelado (PFC) e oito de sangue total (ST), no período de 186 dias. Foi analisado o consumo de hemocomponentes em cada grupo, e na razao do número de Rns vivos por dia, até o 120 dia. Resultados. O consumo médio de hemocomponentes foi de 7,31 unidades para RNPT e 3,46 para RNT. A análise de consumo diário revelou que a maior parte ocorreu em RNs sob tratamento clínico antes do 60 dia de vida (d.v.) e que um aumento após o 86 d.v. pode ser atribuído a um aumento de cirurgias nessa fase. Os acidentes hemorrágicos predominaram em RNPT com plaquetometria inferior a 60.000/mm3. Foi constatada uma tendência inversamente proporcional entre o número de transfusoes e a sobrevida. Conclusoes. Os RNPT consumiram mais hemocomponentes que os RNT. Esse consumo estava ligado à patologia de base. Foi sugerido que a transfusao profilática de CP em RNPT poderia reduzir o número de hemorragias, além do consumo de CH nesse grupo. Mais de dez transfusoes de hemocomponentes nos primeiros 120 d.v., em ambos os grupos, parece constituir marcador de mau prognóstico.
Assuntos
Humanos , Recém-Nascido , Transfusão de Sangue , Doenças do Recém-Nascido/terapia , Recém-Nascido Prematuro , Análise de Sobrevida , Psicologia da Criança , Seguimentos , Transfusão de Componentes SanguíneosAssuntos
Humanos , Criança , Arteriopatias Oclusivas/história , Autopsia , Homocisteína/metabolismo , Peso Molecular , PrevalênciaRESUMO
Aluminum (Al3+) intoxication is thought to play a major role in the development of Alzheimer's disease and in certain pathologic manifestations arising from long-term hemodialysis. Although the metal does not present redox capacity, it can stimulate tissue lipid peroxidation in animal models. Furthermore, in vitro studies have revealed that the fluoroaluminate complex induces diacyglycerol formation, 43-kDa protein phosphorylation and aggregation. Based on these observations, we postulated that Al3+-induced blood platelet aggregation was mediated by lipid peroxidation. Using chemiluminescence (CL) of luminol as an index of total lipid peroxidation capacity, we established a correlation between lipid peroxidation capacity and platelet aggregation. Al3+ (20-100 muM) stimulated CL production by human blood platelets as well as their aggregation. Incubation of the platelets with the antioxidants nor-dihydroguaiaretic acid (NDGA) (100 muM) and n-propyl gallate (NPG) (100 muM), inhibitors of the lipoxygenase pathway, completely prevented CL and platelet aggregation. Acetyl salicylic acid (ASA) (100 muM), an inhibitor of the cyclooxygenase pathway, was a weaker inhibitor of both events. These findings suggest that Al3+ stimulates lipid peroxidation and the lipoxygenase pathway in human blood platelets thereby causing their aggregation.
Assuntos
Humanos , Adulto , Alumínio/farmacologia , L-Lactato Desidrogenase/análise , Lignanas/farmacologia , Peroxidação de Lipídeos/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Galato de Propila/farmacologia , Ristocetina/farmacologia , Salicilatos/farmacologia , Alumínio/análise , Medições LuminescentesRESUMO
Twenty-four surgical patients of both sexes without cardiac, hepatic, renal or endocrine dysfunctions were divided into two groups: 10 cardiac surgical patients submitted to myocardial revascularization and cardiopulmonary bypass (CPB), 3 females and 7 males aged 65 ñ 11 years, 74 ñ 16 kg body weight, 166 ñ 9 cm height and 1.80 ñ 0.2l m2 body surface area (BSA), and control, 14 surgical patients not submitted to CPB, 11 female and 3 males aged 41 ñ 14 years, 66 ñ 14 kg body weight, 159 ñ 9 cm height and 1.65 ñ 0.16 m2 BSA (mean ñ SD). Sodium diclofenac (1 mg/kg, im Voltaren 75( twice a day) was administered to patients in the Recovery Unit 48 h after surgery. Venous blood samples were collected during a period of 0-12 h and analgesia was measured by the visual analogue scale(VAS) during the same period. Plasma diclofenac levels were measured by high performance liquid chromatography. A two-compartment open model was applied to obtain the plasma decay curve and to estimate kinetic parameters. Plasma diclofenac protein binding decreased whereas free plasma diclofenac levels were increased five-fold in CPB patients. Data obtained for analgesia reported as the maximum effect (EMA were: 25 per cent VAS (CPB) vs 1O per cent VAS (control), P<0.05, median measured by the visual analogue scale where lOO per cent is equivalent to the highest level of pain. To correlate the effect versus plasma diclofen levels, the EMAX sigmoid model was applied. A prolongation of the mean residence time for maximum effect (MRTEMAX) was observed without any change in lag-time in CPB in spite of the reduced analgesia reported for these patients, during the time-dose interval. In conclusion, the extent of plasma diclofenac protein binding was influenced by CPB with clinicall relevant kinetic-dynamic consequences.
Assuntos
Humanos , Feminino , Adulto , Idoso , Pessoa de Meia-Idade , Ponte Cardiopulmonar/reabilitação , Diclofenaco/administração & dosagem , Ligação Proteica/efeitos dos fármacos , Analgesia , Diclofenaco/metabolismo , Diclofenaco/uso terapêuticoRESUMO
A method which permits the simultaneous HPLC analysis of antipyrine (A), 3-hydroxymethylantipyrine (HMA), 4-hydroxyantipyrine (HOA) and norantiopyrine (NORA) using a single extraction step in a five minute chromatographic run is described. Only 500 micraLitro of urine were necessary for the quantitation of all compounds investigated. An analog derivative, 4-aminoantipyrine, was used as internal standard (IS). Urine samples were hydrolyzed with Limpet acetone powder, 37 graus centigrados, pH 5.0 for 2 h. Sodium chloride was added and urine samples were extracted with diclhormethane-isopropyl alcohol (90:10, v/v) in acidic medium. The residue was dissolved with mobile phase, washed with n-hexane and 20 micralitro of the lower phase were injected into a 4-micron Nova-Pak (R) 'C IND. 18' column. Peaks monitored at 254 nm were eluted with 0.75 M sodium acetate buffer, pH 5.0: methanol, (70:30, v/v) as mobile phase. The method, validated on the basis of the confidence limits for antipyrine and its metabolites, presented good stability, sensitivity, linearity, and intra or interassay precisions lower than 5 percente for all commpounds were investigated. This assay was applied for drug metabolism study carried out in ten healthy volunteers: 23 about 5 yr and 63 about 10 kg(mean about SD) after p.o. single dose of antipyrine, 500 mg/capsule. Diuresis of 24 h up to 72 h of drug administration was preserved with sodium metabisulfite, 4 mg/mL. Biological fluids were stored at -20 centigrade degree until assay. The main hydroxy-metabolites (HMA + HOA) and NORA, minor N-demethylated metabolite of antipyrine, were excreted: 60 percent and 20 percente as percentage of the given dose, respectively. Clearances for production of metabolites expressed as mL/min, were: 8.61 about 4.28 (7.24) for HMA, 13.91 about 6.20(12.67) for HOA, and 8.08 about 4.01(5.93) for NORA, mean about SD (median).
Assuntos
Humanos , Pré-Escolar , Criança , Adolescente , Adulto , Antipirina/análise , Antipirina/metabolismo , Cromatografia , FarmacologiaRESUMO
O teste ELISA ant-HTLVI/II foi introduzido na triagem sorlógica de doadores de sangue na Fundaçäo Pró-sangue Hemocentro de Säo Paulo (FPS/HSP) em julho de 1991. NO período compreendido entre julho de 1991 e julho de 1994 foram submetidos à triagem serológica 597.727 doadores. Destes, 7682 foram recusados por terem apresentado reatividade no teste ELISA anti-HTLVI/II. A positividade observada, para o referido teste, foi diminuindo com o correr do tempo: 2,12 por cento em 1991; 1,6 por cento em 1992; 0,8 por cento em 1993 e 1,0 por cento em 1994, sendo esse fato atribuido a melhora da especialidade e reprodutividade dos kits comerciais. Foi utilizado o teste suplementar de Western Blot para confirmar os resultados dos testes ELISA. Em 249 amostras de soros de doadores, com resultado repetidamente positivo (RRP) no teste ELISA (hemobio), o poder confirmatório do Western Blot (Cambridge Biotech) foi de 24.9 por cento (IC/90 por cento: 20,4 por cento-29,39 por cento). Baseados nesses dados, considera-se uma expectativa de prevalência de indivíduos infectados pelo HTLVI/II, na populaçäo de doadores de sangue da FPS/HSP de 0,142 por cento (IC/90 por cento; 0,116 por cento-0,167 por cento). Em 437 amostras de soro de doadores que retornaram ao Banco de Sangue, para confirmar o resultado inicial e apresentaram RRP no teste ELISA, o poder confirmatório do Western Blot foi de 34,55 por cento (IC/90 por cento: 30,82 por cento-38,28 por cento)...
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Doadores de Sangue , Anticorpos Anti-HTLV-I/isolamento & purificação , Anticorpos Anti-HTLV-II/isolamento & purificação , Infecções por HTLV-I/epidemiologia , Infecções por HTLV-II/epidemiologia , Western Blotting , Ensaio de Imunoadsorção Enzimática , PrevalênciaRESUMO
The in vitro and ex vivo effect of therapeutic levels of papaverine on human platelet aggregation induced by 3-5 uM adenosine-5-diphosphate (ADP) was evaluated in platelet-rich plasma (PRP) by photometric and impedance aggregometry and in whole blood by impedance aggregometry. Platelet aggregation induced by 3-5 uM ADP in whole blood was significantly inhibited by 5.32 and 10.64 uM papaverine in vitro. This effect was also observed in PRP enriched with erythrocytes but not in PRP alone of enriched with leukocytes. Papaverine (5.32 uM) significantly enhanced the antiplatelet activity of adenosine (0.75 uM) in human whole blood, an effect that was not observed in PRP. A single oral dose of 100 mg papaverine hydrochloride, given to eight healthy human volunteersa 1 h before the platelet aggregation evaluation, significantly inhibited the platelet aggregation induced by 3-5 uM ADP in whole blood. This effect was not observed in PRP. Oral administration of the same dose at 8-h intervals (10 times) to seven additional healthy human volunteers led to a significant negative correlation (r+0.55, P<0.01) between the slope of platelet aggregation in whole blood and plasma papaverine levels )0.12-0.75 uM). Papaverine and adenosine, alone or together, had no in vitro effect on whole blood platelet aggregation of male Wistar rats measured by impedance aggregometry. These results suggest that papaverine inhibits human platelet aggregation in whole blood by an intgeraction with red blood cells
Assuntos
Ratos , Adenosina , Agregação Plaquetária/induzido quimicamente , Técnicas In Vitro , Papaverina/antagonistas & inibidoresRESUMO
The effects of an aqueous extract of guaraná (Paullinia cupana) on rabbit platelet aggregation and thromboxane synthesis were examined. The guaraná extract (100 mg/ml) and fractions separated by TLC (origin and xanthines) decreased platelet aggregation (37.27 and 31% of control values, respectively) and platelet thromboxane formation from [14C]-arachidonic acid (78, 70 and 50% of control values respectively). The decreased thromboxane synthesis could be responsible, at least in part, for the antiaggregatory action of guaraná
Assuntos
Animais , Coelhos , Extratos Vegetais/farmacologia , Plantas Medicinais , Inibidores da Agregação Plaquetária , Tromboxanos/biossíntese , Agregação PlaquetáriaRESUMO
Adults with pulmonary hypertension and polycythemia (N=22) have low levels of plasma antithrombin III (84 ñ 18 vs 98 ñ 13½ for controls, N=35, P<0.005) and protein C (66ñ21 vs 125 ñ 30%, N 8, P<0.0002 but normal levels of total protein S. Data are reported as means ñ SD and percent normal values obtained for pooled plasma from normal healthy adults. Children with the same disorder (N = 6) also had low protein C levels (66 ñ 16 vs 85 ñ 5½, P < 0.025). Total protein S was normal for children, but free protein S was decreased (66 ñ 13 vs 91 ñ 23,, P < 0.02). Since the levels observed in these patients are above those reported for congenital deficiencies, the reduction in plasma levels of anticoagulant proteins may be the result of cronic intravascular coagulation. Furthermore, normal levels of plasminogen and fibrin degradation products suggested a localized disorder or an acquired decrease in fibronolytic activity
Assuntos
Humanos , Adulto , Antitrombina III/análise , Complexo de Eisenmenger/sangue , Glicoproteínas/sangue , Proteína C/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinólise , HematócritoRESUMO
Seven patients submitted to myocardial revascularization surgery with cardiopulmonary bypass were studied. Blood samples were obtained immediately before and 24 h after surgery. The parameters studied were the production of platelet activating factor (PAF-acether) and superoxide anion, cellular beta-glucuronidase activity as well as polymorphonuclear cell(PMN) and platelet count. Twenty-four h after surgery, there was a 54% decrease in platelet number (P<0.005), a 121% increase in PMN number (P<0.005), a 353% increase in PAF-acether (P<0.01), a 211% increase in superoxide anion (O2-) and a 104% increase in beta-glucuronidase (P<0.05) levels when compared with the pre-surgery levels. The present results indicate that PMN are more reactive after surgery with cardiopulmonary bypass